GlassScriptPhysician profile
Robert I Laugherty
NPI 1932368552
$122,299.48
in general payments reported to CMS, 2019-2025
22 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $26K · 2023: $33K · 2024: $21K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Travel and Lodging: $12K · Consulting Fee: $7,898 · Food and Beverage: $7,323 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,102.50 |
| Travel and Lodging | $11,700.61 |
| Consulting Fee | $7,897.50 |
| Food and Beverage | $7,322.71 |
| Education | $268.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58,783.01 | 2021-2025 | Taltz |
| Amgen INC. | $23,091.08 | 2021-2025 | Otezla, Otezla, Enbrel |
| Eli Lilly and Company | $15,509.13 | 2023-2024 | Taltz |
| Ucb, INC. | $15,306.56 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,996.41 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,194.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $930.60 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $750.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $744.08 | 2021-2025 | |
| Pfizer INC. | $500.19 | 2021-2025 | |
| Radius Health, INC. | $283.33 | 2021-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $243.79 | 2022-2025 | Acthar |
| Glaxosmithkline, LLC. | $181.68 | 2021-2022 | |
| Horizon Therapeutics Plc | $181.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $129.98 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $114.02 | 2021-2023 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $93.12 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $90.67 | 2021-2022 | |
| Sandoz INC. | $79.99 | 2024-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.24 | 2022 | |
| Sobi, INC | $19.11 | 2024 | |
| Novo Nordisk INC | $14.52 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Laugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.